Foundry Partners, LLC Seagen Inc. Transaction History

Foundry Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$191.51 - $216.16 $124,481 - $140,504	-650 Reduced 29.23%	1,574 $333,000
Q1 2023 May 03, 2023	SELL	$127.59 - $203.08 $4,338 - $6,904	-34 Reduced 1.51%	2,224 $450,000
Q3 2022 Oct 21, 2022	BUY	$135.27 - $180.11 $78,727 - $104,824	582 Added 34.73%	2,258 $309,000
Q2 2022 Jul 28, 2022	BUY	$108.81 - $179.33 $182,365 - $300,557	1,676 New	1,676 $297,000
Q1 2022 Apr 14, 2022	SELL	$119.61 - $157.85 $170,085 - $224,462	-1,422 Closed	0 $0
Q3 2021 Oct 14, 2021	BUY	$142.45 - $169.82 $3,846 - $4,585	27 Added 1.94%	1,422 $241,000
Q2 2021 Jul 23, 2021	BUY	$135.08 - $161.1 $188,436 - $224,734	1,395 New	1,395 $220,000
Q1 2021 May 12, 2021	SELL	$137.51 - $190.8 $191,826 - $266,166	-1,395 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$164.63 - $211.93 $60,089 - $77,354	365 Added 35.44%	1,395 $244,000
Q3 2020 Oct 23, 2020	BUY	$145.95 - $195.69 $150,328 - $201,560	1,030 New	1,030 $202,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.